Evidence map›Paper›PMID 31386050›Full record

ArticleNeuro-oncology practice2019

Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.

Huy Tram Nguyen, Nhung Nguyen, Liang Yen Liu, Laura Dovek, Daniel Lenchner, Robert Harris, Byram Ozer, Arliene Ravelo, Nicolas Sommer, Myung Shin Sim and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Huy Tram NguyenDepartment of Neurology, University of California, Los Angeles, California, USA.
Nhung NguyenDepartment of Neurology, University of California, Los Angeles, California, USA.
Liang Yen LiuDepartment of Neurology, University of California, Los Angeles, California, USA.
Laura DovekDepartment of Neurology, University of California, Los Angeles, California, USA.
Daniel LenchnerDepartment of Neurology, University of California, Los Angeles, California, USA.
Robert HarrisDepartment of Radiological Sciences and Biomedical Physics, University of California, Los Angeles, California, USA.
Byram OzerDepartment of Neurology, University of California, Los Angeles, California, USA.
Arliene RaveloGenentech Inc, San Francisco, California, USA.
Nicolas SommerGenentech Inc, San Francisco, California, USA.
Myung Shin SimDepartment of Biomathematics, University of California, Los Angeles, California, USA.
Robert ElashoffDepartment of Biomathematics, University of California, Los Angeles, California, USA.
Richard GreenKaiser Permanente Southern California, Los Angeles, California, USA.
Phioanh Leia NghiemphuDepartment of Neurology, University of California, Los Angeles, California, USA.
Timothy Francis CloughesyDepartment of Neurology, University of California, Los Angeles, California, USA.
Benjamin EllingsonDepartment of Radiological Sciences and Biomedical Physics, University of California, Los Angeles, California, USA.ORCID 0000-0002-2764-6640
Albert LaiDepartment of Neurology, University of California, Los Angeles, California, USA.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

backgroundSince its approval for use in recurrent glioblastoma (GBM), the survival benefit of bevacizumab (Bev) remains to be demonstrated. To address this issue, we retrospectively examined survival from first recurrence in patients treated with Bev, lomustine (CCNU), or Bev/CCNU.

methodsWe identified 168 primary GBM patients diagnosed at UCLA and Kaiser Permanente LA who received upfront radio-chemotherapy, followed by Bev and/or CCNU at first recurrence. Three patient groups, contemporaneously diagnosed from 2009 through 2015, were identified: (1) patients treated with Bev alone (n = 49), (2) CCNU alone (CCNU 09-15) (n = 36), and (3) Bev/CCNU (n = 53). Another CCNU control group (n = 30) diagnosed from 2001 through 2004 (CCNU 01-04) was also derived. We measured tumor size at first recurrence treatment initiation, using bidimensional (2D) and volumetric (3D) techniques, and analyzed overall survival (OS) from first recurrence.

resultsAmong the entire cohort, larger tumor size at first recurrence was associated with poorer survival. The CCNU 01-04 group had similar tumor size as the Bev arms and low Bev crossover (7%). Treatment with Bev was associated with improved survival in patients with large tumor 2D measurements: Median OS for Bev and Bev/CCNU groups were 6.71 mo (n = 27) and 6.97 mo (n = 36) vs 4.03 mo (n = 10) in CCNU 01-04. Analysis by 3D measurement yielded similar results. Interestingly, the CCNU 09-15 group showed the highest survival, likely due to smaller tumor size and crossover to Bev (69%).

conclusionSurvival advantage from Bev treatment was observed only among patients with large tumor burden as determined by either 2D or 3D measurement.

Indexed as

bevacizumabfirst recurrenceglioblastomaoverall survivaltumor size

Identifiers

PMID31386050
PMCPMC6656330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.